Tesarossa
Htn | 6’1 | 22.5” Bidelt | Fuoty 3026 ⚝
- Joined
- Jan 3, 2026
- Posts
- 13,441
- Reputation
- 34,996
Table Of Content
Dosing
Pricing
Where To Find
Side Effects
Pathways
Thread Song
Story
Dosing
Pricing
Where To Find
Side Effects
Pathways
Thread Song
Story
In the busy city of Growth Plate, the bossy FGFR3 sat on his throne and told all the little bone cells to stop growing. “No more stretching!” he yelled, keeping everything short and stuck. Then Meclizine, the friendly motion sickness medicine, wandered in by accident. “Oops, wrong place!” he said with a smile. He wasn’t a big hero, just an old helper who calmed queasy stomachs, but he gently quieted FGFR3’s noisy signals.
The frozen cells woke up, stretched, and started growing again. FGFR3 got mad and tried to shout louder, but Meclizine just kept saying “oops, my bad” while turning the volume down. The bones got a little longer, the arms reached farther, and everyone felt happier. Meclizine tipped his hat and left humming. “Didn’t mean to start a fight,” he said. “Just wanted to give the place a little more room to grow.”
The frozen cells woke up, stretched, and started growing again. FGFR3 got mad and tried to shout louder, but Meclizine just kept saying “oops, my bad” while turning the volume down. The bones got a little longer, the arms reached farther, and everyone felt happier. Meclizine tipped his hat and left humming. “Didn’t mean to start a fight,” he said. “Just wanted to give the place a little more room to grow.”
MEClOIZINE
Meclizine (also spelled meclozine) is an established H1 antihistamine primarily used for motion sickness and vertigo. Through drug repurposing research, it has been identified as an inhibitor of FGFR3 signaling and investigated as a potential oral therapy for achondroplasia (ACH) and related FGFR3 driven skeletal dysplasias.
It is not a classical tyrosine kinase inhibitor that directly blocks the FGFR3 kinase domain. Instead, it acts downstream in the pathway.
✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
Background
Achondroplasia is caused by gain of function mutations in FGFR3 (most commonly G380R). Excess FGFR3 signaling (via the RAS-RAF-MEK-ERK/MAPK cascade and other pathways) inhibits chondrocyte proliferation and differentiation in the growth plate, leading to short-limbed short stature and other skeletal features.
Researchers screened FDA approved drugs and found that meclizine attenuates abnormally activated FGFR3 signaling in chondrocytes. Key findings include:
- It facilatates chondrocyte proliferation and differentiation.
- It mitigates loss of extracellular matrix
- It downregulates phosphorylation of ERK (but not MEK) in FGFR2 Treated cells
- It rescues growth hormone inhibition caused by constitutively active MEK or RAF mutants but not ERK mutants, pointing to can an action at or near MEK to ERK step (or higher in some contexts.)
- Effects are comparable in potency to c-type natriuretic peptide (CNP) in some experimental systems.
Preclinical Evidence
In cell lines (RCS rat chondrosarcoma, HCS-2/8 human chondrosarcoma expressing ACH, thanatophoric dysplasia, or SADDAN FGFR3 mutants) and embryonic bone explant cultures, meclizine rescued suppressed proliferation and promoted longitudinal growth.
In Fgfr3ach transgenic mice (ACH model), oral meclizine (typically 1–2 mg/kg/day, sometimes twice daily) increased body length, long bone lengths (femur, tibia, etc.), cranial and vertebral measurements, bone volume, and trabecular quality. Effects were dose dependent and observed at plasma exposures achievable with standard human anti motion sickness doses.
Combination with growth hormone (GH) in mice improved bone length (no clear additive effect on length) and showed additive benefits on bone mineral density growth plate histology differed between the agents.
✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
Clinical Development
Phase 1a: Single doses (25 or 50 mg) were safe. Pharmacokinetics (PK) supported further study, steady state was simulated around day 10 with repeated dosing.
Phase 1b: 14-day repeated dosing (12.5 mg/day for <20 kg; 25 mg/day for > 20 kg, after meals). No serious adverse events. Mild events included abdominal pain, vomiting, somnolence, and one moderate mouth ulcer. Steady state concentrations were reached, AUC and Cmax were dose dependent. Recommended regimen for longer trials: 12.5 mg (<20 kg) or 25 mg (>20 kg) daily.
✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
Pharmacokinetics
Oral absorption; Tmax typically ~1.7–3.7 hours.
Half life 5–8.5 hours (somewhat longer in children with ACH in some reports).
In ACH children (12.5 mg repeated): approximate mean Cmax -167 ng/mL, AUC0–24h - 1170 ng h/mL, t1/2 - 7.4 h.
✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
Side Effects (Common And Less Common)
Common:
drowsiness
dry mouth
fatigue
headache
vomiting
Less Common
blurred vision
urinary retention
rare anaphylaxis
✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
Dosage
An optimal dose for longitudal-growth is around 50-100 mgs per day.
Where to find
100 25mg tablets are literally 6 bucks on amazon
https://a.co/d/03bN5bnR✧˖°── .✦────☼༺☆༻☾────✦.── °˖✧
@Nerogen thanks for telling me abt this i lwky ended up making it before you sorry bro
@Stalker @blinkers @hate @iblamemyhabits
Edit: I forgot the story it should be there now
How am i dropping guides daily?
Last edited:
i found this out and u js take it from me
